The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 360:1147-1150 March 12, 2009 Number 11
NextNext

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Jamerson, K.
-PubMed Citation
To the Editor: In their report on the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, Jamerson et al. (Dec. 4 issue)1 challenge current treatment recommendations for hypertension. In the study, they reported that the use of combined therapy with an angiotensin-converting–enzyme (ACE) inhibitor, benazepril, plus a calcium-channel blocker, amlodipine, was superior to that of benazepril plus a thiazide diuretic, hydrochlorothiazide, in reducing cardiovascular events. However, an analysis that is based on potassium levels or the presence of hypokalemia may explain differences between the two study groups. In the Systolic Hypertension in the Elderly . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.